Comparison
Cagrilintide vs. Bremelanotide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Research other
CAS no.
1415456-99-3
189691-06-3
Molecular weight
4253.7 g/mol
1025.18 g/mol
Half-life
168 h
2.7 h
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYAc-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHMechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
5
of which in humans
3
5
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
2